CIMERLI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CIMERLI (CIMERLI).
CIMERLI (ranibizumab-eqrn) is a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF-A isoforms (e.g., VEGF110, VEGF121, VEGF165) and prevents their interaction with receptors VEGFR-1 and VEGFR-2 on endothelial cells, thereby inhibiting angiogenesis and reducing vascular permeability.
| Metabolism | Metabolism is not fully characterized; ranibizumab is a monoclonal antibody fragment and is expected to be degraded by proteolytic enzymes into small peptides and amino acids via general protein catabolism. |
| Excretion | Primarily eliminated via intracellular catabolism; urinary excretion of intact drug is negligible (<0.1%). Biliary/fecal excretion of intact drug is minimal. No renal or hepatic metabolism in the classical sense. |
| Half-life | Terminal elimination half-life: 5.9 days (range 4.0–7.5 days) in patients with neovascular AMD after intravitreal administration. This supports monthly or bimonthly dosing intervals. |
| Protein binding | No data on specific binding proteins; as a monoclonal antibody, minimal to no binding to plasma proteins is expected (likely <5% binding). |
| Volume of Distribution | Central compartment volume: approximately 3–4 L (0.04–0.06 L/kg) after intravitreal injection, reflecting distribution within the eye and systemic circulation (primarily confined to vitreous humor and plasma). |
| Bioavailability | Intravitreal injection: 100% (direct administration into vitreous humor). Not administered via other routes. |
| Onset of Action | Intravitreal injection: Onset of visual improvement is observed within 1–2 weeks, with maximal effect on retinal thickness by 4 weeks as seen in clinical trials. |
| Duration of Action | Approximately 4–6 weeks based on visual acuity stabilization and optical coherence tomography (OCT) parameters. Monthly dosing maintains efficacy; bimonthly dosing after initial loading may be used. |
0.5 mg (0.05 mL) administered by intravitreal injection once monthly (approximately every 28 days).
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required based on GFR; renal impairment does not affect systemic exposure. |
| Liver impairment | No dose adjustment recommended for hepatic impairment, as systemic exposure is minimal. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy in children have not been established. |
| Geriatric use | No specific dose adjustment required; clinical studies included patients aged 65 and older with no observed differences in efficacy or safety. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CIMERLI (CIMERLI).
| Breastfeeding | No data on presence in human milk; systemic absorption after intravitreal injection is negligible (<0.1% of serum levels). M/P ratio not established. Caution: likely minimal excretion but due to potential adverse effects on developing retinal vasculature, consider risk-benefit. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate human studies; in animal studies, administration of ranibizumab (CIMERLI is a biosimilar) resulted in embryofetal toxicity at doses ≥0.25 mg/kg/day (0.1 mg/kg/day in humans by IVT). Organogenesis: increased fetal resorptions and skeletal variations. Second and third trimesters: theoretical risk of VEGF inhibition potentially affecting renal development and fetal growth. Use only if potential benefit justifies potential risk. |
■ FDA Black Box Warning
Endophthalmitis and retinal detachments: Intravitreal injections, including those with CIMERLI, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must be used.
| Serious Effects |
["Ocular or periocular infections","Active intraocular inflammation","Hypersensitivity to ranibizumab or any component of the formulation"]
| Precautions | ["Endophthalmitis and retinal detachments: Serious adverse events following intravitreal injection.","Increase in intraocular pressure (IOP): Transient increase has been seen within 60 minutes of injection; sustained increases may require monitoring and management.","Arterial thromboembolic events (ATEs): Potential risk, though the rate in clinical trials was low. Use with caution in patients with prior stroke or transient ischemic attack.","Ocular adverse events: Including intraocular inflammation, vitreous floaters, and conjunctival hemorrhage."] |
Loading safety data…
| Fetal Monitoring | Monitor intraocular pressure (IOP) within 30 minutes post-injection. Assess for endophthalmitis, retinal detachment, or thromboembolic events. In pregnant women, monitor fetal growth and amniotic fluid index if repeated dosing, although systemic exposure is low. |
| Fertility Effects | No human studies; in animal studies, no impairment of fertility at doses up to 0.1 mg/kg/day. Theoretical risk of VEGF inhibition on corpus luteum function and implantation; significance in humans unknown. |